Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease (KFO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2013 by University of Leipzig
Sponsor:
Information provided by (Responsible Party):
Robert Hoellriegel, University of Leipzig
ClinicalTrials.gov Identifier:
NCT00510588
First received: August 1, 2007
Last updated: July 25, 2013
Last verified: July 2013
  Purpose

Chronic inflammatory activation in fat tissue can be the link between adiposity and an increased risk for atherosclerosis. Aim of the study is to investigate how molecular alterations in fat tissue can be influenced by regular physical exercise training alone or in combination with a medical therapy (Glitazon or Metformin) in obese patients with stable CAD and impaired glucose tolerance.


Condition Intervention
Stable Coronary Artery Disease
Obesity
Impaired Glucose Tolerance
Other: training
Other: training + metformin
Other: training + glitazon

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by University of Leipzig:

Primary Outcome Measures:
  • change in endothelial function in patients with stable coronary artery disease [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • change in metabolic parameters [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: July 2007
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
regular physical exercise training
Other: training
regular physical exercise training for 6 months
2
regular physical exercise training + metformin
Other: training + metformin
regular physical exercise training in combination with metformin for 6 months
3
regular physical exercise training + glitazon
Other: training + glitazon
regular physical exercise training in combination with a glitazon for 6 months
No Intervention: 4
Control

  Eligibility

Ages Eligible for Study:   35 Years to 75 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • either impaired glucose tolerance (2-h plasma glucose concentration >7.8 and <11.1 mmol/L during an oral glucose tolerance test) or impaired fasting glucose (fasting glucose concentration >6.0 and <7.0 mmol/L)
  • coronary artery disease determined by coronary angiography
  • BMI > 25
  • male patients aged 35-75 years

Exclusion Criteria:

  • diabetes mellitus type 1
  • diabetes mellitus type 2 in combination with glycosylates hemoglobin >6.0%, previous medication with oral antidiabetic agents or insulin, fasting plasma glucose concentration > 11.0 mmol/L
  • unstable angina pectoris
  • indication for coronary artery bypass graft operation
  • myocardial infarction within the last 3 months
  • reduced left-ventricular systolic function < 40 %
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00510588

Contacts
Contact: Axel Linke, MD 0049-341-8651672 linkea@medizin.uni-leipzig.de

Locations
Germany
University of Leipzig - heart center Recruiting
Leipzig, Germany, 04289
Sponsors and Collaborators
University of Leipzig
Investigators
Principal Investigator: Gerhard Schuler, Prof. of medicine University of Leipzig
  More Information

No publications provided

Responsible Party: Robert Hoellriegel, Co-Investigator, University of Leipzig
ClinicalTrials.gov Identifier: NCT00510588     History of Changes
Other Study ID Numbers: 0815-2007
Study First Received: August 1, 2007
Last Updated: July 25, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Leipzig:
adiposity

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Obesity
Glucose Intolerance
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 23, 2014